A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a well-established class of glucose-lowering drugs. GLP-1 RAs can be classified according to their structure, duration of action and mode of administration. This review describes the basic and clinical pharmacology of orally administered sema...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalra, Sanjay, Sahay, Rakesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434819/
https://www.ncbi.nlm.nih.gov/pubmed/32725484
http://dx.doi.org/10.1007/s13300-020-00894-y
_version_ 1783572215300620288
author Kalra, Sanjay
Sahay, Rakesh
author_facet Kalra, Sanjay
Sahay, Rakesh
author_sort Kalra, Sanjay
collection PubMed
description Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a well-established class of glucose-lowering drugs. GLP-1 RAs can be classified according to their structure, duration of action and mode of administration. This review describes the basic and clinical pharmacology of orally administered semaglutide. It highlights the PIONEER clinical trial programme results, and reviews the efficacy, safety and tolerability.
format Online
Article
Text
id pubmed-7434819
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-74348192020-08-24 A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus Kalra, Sanjay Sahay, Rakesh Diabetes Ther Review Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a well-established class of glucose-lowering drugs. GLP-1 RAs can be classified according to their structure, duration of action and mode of administration. This review describes the basic and clinical pharmacology of orally administered semaglutide. It highlights the PIONEER clinical trial programme results, and reviews the efficacy, safety and tolerability. Springer Healthcare 2020-07-28 2020-09 /pmc/articles/PMC7434819/ /pubmed/32725484 http://dx.doi.org/10.1007/s13300-020-00894-y Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Review
Kalra, Sanjay
Sahay, Rakesh
A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus
title A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus
title_full A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus
title_fullStr A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus
title_full_unstemmed A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus
title_short A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus
title_sort review on semaglutide: an oral glucagon-like peptide 1 receptor agonist in management of type 2 diabetes mellitus
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434819/
https://www.ncbi.nlm.nih.gov/pubmed/32725484
http://dx.doi.org/10.1007/s13300-020-00894-y
work_keys_str_mv AT kalrasanjay areviewonsemaglutideanoralglucagonlikepeptide1receptoragonistinmanagementoftype2diabetesmellitus
AT sahayrakesh areviewonsemaglutideanoralglucagonlikepeptide1receptoragonistinmanagementoftype2diabetesmellitus
AT kalrasanjay reviewonsemaglutideanoralglucagonlikepeptide1receptoragonistinmanagementoftype2diabetesmellitus
AT sahayrakesh reviewonsemaglutideanoralglucagonlikepeptide1receptoragonistinmanagementoftype2diabetesmellitus

Ejemplares similares